Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics ( (AU:TYP) ) has shared an announcement.
Tryptamine Therapeutics has established a framework for a world-first clinical trial to treat Binge Eating Disorder (BED) using TRP-8803, in collaboration with Swinburne University. The trial aims to assess the safety and efficacy of TRP-8803, administered with psychotherapy, in BED patients, potentially impacting the treatment landscape for this prevalent disorder in the US and Australia.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing TRP-8803, a proprietary psilocin-based, IV-infused formulation with neuroplastic benefits.
Average Trading Volume: 1,474,349
Technical Sentiment Signal: Sell
Current Market Cap: A$46.05M
Find detailed analytics on TYP stock on TipRanks’ Stock Analysis page.